
    <!DOCTYPE html>
        <html>
        <head>
        <meta content="width=device-width, initial-scale=1" name="viewport" />
        <style>


@media only screen and (min-width:601px){
  .all {
    padding-left: 35%;
    padding-right: 35%;
    
  }
}

@media only screen and (max-width: 600px) {
  .all {
    padding-left: 5%;
    padding-right: 5%;

  }
}

body {
  margin-bottom:20%;
  padding-top: 5%;
}

h1 {
  text-align: center;
}

a {
  color: black;
  text-decoration: none;
}

.topnav {
  background-color: #333;
  overflow: hidden;
  position: fixed;
  width: 100%;
  top: 0;
  margin-left: 0;
}

.topnav a {
  float: left;
  color: #f2f2f2;
  text-align: center;
  padding: 14px 16px;
  text-decoration: none;
  font-size: 17px;
}

.topnav a:hover {
  background-color: #ddd;
  color: black;
}

.link:hover {
  color: blue;
}
        </style>
        <title>HEALTH SUMMARIES</title>
        </head>
        <body>
        <div class = 'topnav'>
        <a class='active' href='/'> Front Page</a>
        <a href="/news">News</a>
        <a href="/health">Health</a>
        <a href="/pharma">Pharma</a>
        </div>
        <div class='all'><h4>2019-02-12 08:01</h4><h1><a href='https://www.fiercebiotech.com/'>Fierce Biotech</a></h1><h3><a class='link' href='https://www.fiercebiotech.com/medtech/fiercemedtech-s-2018-fierce-15'>FierceMedTech's 2018 Fierce 15</a></h3><h3><a class='link' href='https://www.fiercebiotech.com/biotech/neurogene-nets-68-5m-to-advance-gene-therapies-for-rare-neuro-diseases'>Neurogene nets $68.5M to advance therapies for neuro diseases</a></h3><h3><a class='link' href='https://www.fiercebiotech.com/medtech/philips-unveils-new-epiq-elite-ultrasound-line-vascular-imaging-capabilities'>Philips unveils new EPIQ Elite line of ultrasound systems</a></h3><h3><a class='link' href='https://www.fiercebiotech.com/research/fresh-insights-into-genes-and-macular-degeneration-could-open-new-treatment-pathways'>Fresh insights into genes and AMD could open new drug targets</a></h3><h3><a class='link' href='https://www.fiercebiotech.com/biotech/abbvie-teneobio-ink-90m-deal-to-develop-bcma-bispecific-for-multiple-myeloma'>AbbVie, Teneobio ink $90M deal to develop BCMA bispecific</a></h3><br><h1><a href='https://www.biospace.com/news/'>BioSpace</a></h1><h3><a class='link' href='https://www.biospace.com/article/clinical-trial-transparency-is-improving-particularly-among-larger-companies/'>Interview: Clinical Trial Transparency Is Improving, Particularly Among Larger Companies</a></h3><h3><a class='link' href='https://www.biospace.com/article/5-impressive-questions-to-ask-in-a-final-round-job-interview/'>5 Impressive Questions to Ask in a Final Round Job Interview</a></h3><h3><a class='link' href='https://www.biospace.com/article/releases/new-report-finds-nation-s-public-health-emergencies-are-increasing-while-state-emergency-preparedness-levels-are-mixed-17-states-score-in-top-readiness-tier-20-states-and-dc-in-middle-tier-13-states-in-lower-tier/'>New Report Finds Nation's Public Health Emergencies Are Increasing While State Emergency Preparedness Levels Are Mixed; 17 States Score in Top Readiness Tier, 20 States and DC in Middle Tier, 13 States in Lower Tier</a></h3><h3><a class='link' href='https://www.biospace.com/article/releases/arise-3-study-the-phase-3-clinical-trial-of-the-new-drug-rgn-259-for-the-treatment-of-dry-eye-syndrome-is-initiated-by-regentree/'>ARISE-3 Study, the Phase 3 Clinical Trial of the New Drug RGN-259 for the Treatment of Dry Eye Syndrome is Initiated by ReGenTree</a></h3><h3><a class='link' href='https://www.biospace.com/article/releases/moberg-pharma-ab-year-end-report-2018/'>Moberg Pharma AB Year-end Report 2018</a></h3></div></body>
        </html>